Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging agents that target signaling pathways in cancer stem cells
Yue Yang, Xiaoman Li, Ting Wang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Targeting the Wnt/β-catenin signaling pathway in cancer
Ya Zhang, Xin Wang
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 1072
MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis
Haiwei Ni, Hai Qin, Cheng Sun, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 139
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
Liangliang Xu, Chang Zou, Shanshan Zhang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 114
Metastasis and MAPK Pathways
Mateusz Kciuk, Adrianna Gielecińska, Adrianna Budzinska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3847-3847
Open Access | Times Cited: 102
Unveiling the mechanisms and challenges of cancer drug resistance
Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 101
Current treatments for non-small cell lung cancer
Qianqian Guo, Liwei Liu, Zelong Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 72
The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy
Shangui Liu, Abdur Rauf Khan, Xiaoye Yang, et al.
Journal of Controlled Release (2021) Vol. 335, pp. 1-20
Closed Access | Times Cited: 96
The Role of Iron in Cancer Progression
Qianqian Guo, Liwen Li, Shanshan Hou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 95
Signaling pathways governing breast cancer stem cells behavior
Kai Song, Maryam Farzaneh
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 92
An Insight Into the Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast Cancer
Hina Qayoom, Nissar Ahmad Wani, Bader Alshehri, et al.
Future Oncology (2021) Vol. 17, Iss. 31, pp. 4185-4206
Closed Access | Times Cited: 81
Emerging Role of E2F Family in Cancer Stem Cells
Dan Xie, Pei Qin, Jingyuan Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 71
Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance
Saeedeh Keyvani‐Ghamsari, Khatereh Khorsandi, Azhar Rasul, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 70
CDK1 promotes the stemness of lung cancer cells through interacting with Sox2
Zhen Huang, Guanghui Shen, Ji Gao
Clinical & Translational Oncology (2021) Vol. 23, Iss. 9, pp. 1743-1751
Closed Access | Times Cited: 59
Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis
Haiwei Ni, Guojing Ruan, Cheng Sun, et al.
Environmental Toxicology (2021) Vol. 37, Iss. 2, pp. 192-200
Closed Access | Times Cited: 58
Cancer Stem Cells and Their Possible Implications in Cervical Cancer: A Short Review
Riccardo Di Fiore, Sherif Suleiman, Rosa Drago‐Ferrante, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5167-5167
Open Access | Times Cited: 44
Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies
Maria John Newton Amaldoss, Jia‐Lin Yang, Pramod Koshy, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 12, pp. 103386-103386
Closed Access | Times Cited: 42
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Hui Ming, Bowen Li, Jingwen Jiang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 30
Potential roles and molecular mechanisms of bioactive ingredients in Curcumae Rhizoma against breast cancer
Peng Zhao, Jianfei Qiu, Chaolan Pan, et al.
Phytomedicine (2023) Vol. 114, pp. 154810-154810
Closed Access | Times Cited: 24
PD-1/PD-L1 and DNA Damage Response in Cancer
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska‐Kołat, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 530-530
Open Access | Times Cited: 23
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs
Qi Zhao, Hong Zong, Pingping Zhu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells
Kai Zhang, Wenhao Hu, Feng Li, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 8, pp. 1337-1347
Closed Access | Times Cited: 11
The crosstalk between oncogenic signaling and ferroptosis in cancer
Qianghu Pang, Zhirou Tang, Lianxiang Luo
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104349-104349
Closed Access | Times Cited: 9
Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies
Yunhan Tan, Siyuan Qin, Zhe Zhang, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 1
Open Access | Times Cited: 1
A novel USP4 inhibitor that suppresses colorectal cancer stemness by promoting β-catenin and Twist1 degradation
Fengtian Li, Yi Zhou, Xinyue Lin, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Gillian Horne, Jon Stobo, Caroline Kelly, et al.
Leukemia (2020) Vol. 34, Iss. 7, pp. 1775-1786
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top